Autres langues Intervacc AB

Actions

IVACC

SE0009607252

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Stockholm 18:00:00 07/10/2026			Varia. 5j.	Varia. 1 janv.
0,8980 ^SEK	-3,44%		-11,44%	-2,81%

20/08	Intervacc AB (publ) publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
20/08	Calendrier du jeudi 20 août	FW

Autres langues

15/09	Intervacc to present at upcoming International Healthcare Conference
01/09	Intervacc: Highlights from DNB Carnegie’s Micro Cap Day
24/08	Intervacc (Q2 Review): Key catalysts nearing
21/08	Intervacc: In the right direction – Q2 review
20/08	Intervacc AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
20/08	Intervacc (Q2 initial take): Few surprises – all eyes on the label extension
30/07	Intervacc Submits Type Ii Variation Application to Ema Seeking 12-Month Duration of Immunity for Strangvac
30/07	Intervacc Seeks EU Regulatory Approval to Extend Horse Vaccine's Immunity Duration
30/07	Intervacc submits Type II variation to EMA seeking 12-month duration of immunity for Strangvac
29/07	Intervacc Gets Special Approval to Send Equine Vaccine to New Zealand
29/07	Intervacc: New Zealand order validates Strangvac’s position
29/07	Intervacc AB Publ Makes First Export Of Strangvac To New Zealand Under Special Circumstances Permit
29/07	Intervacc makes first export of Strangvac to New Zealand under Special Circumstances Permit
04/06	Redeye initiates coverage of Intervacc
22/05	Intervacc: Positive results
22/05	Intervacc completes successful evaluation of US strain of strangles pathogen ahead of clinical trials
22/05	Intervacc AB Completes Successful Evaluation of Us Strain of Strangles Pathogen Ahead of Clinical Trials
15/05	Intervacc: US progress, while European sales still soft – Q1 review
15/05	Sweden's Intervacc Elects New Chair
15/05	Appoints Emil Billbäck as chairman
15/05	Emil Billbäck appointed new Chair of the Board of Intervacc
13/05	Intervacc elects Emil Billbäck as chairperson of board
13/05	Report from Annual General Meeting in Intervacc
13/05	Intervacc AB Announces Board Changes
13/05	Intervacc Q1 net sales down at SEK 3.4 million